(Q35585225)

9 August 2017

1 reference

title

Ezetimibe: a selective cholesterol absorption inhibitor (English)

1 reference

9 August 2017

Ezetimibe: A Selective Cholesterol Absorption Inhibitor (English)

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.14.1463.31942

2 April 2024

1

Edith A. Nutescu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14620392

2 April 2024

author name string

Nancy L. Shapiro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14620392

2 April 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

9 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1592%2Fphco.23.14.1463.31942

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.14.1463.31942

https://onlinelibrary.wiley.com/doi/full/10.1592/phco.23.14.1463.31942

2 April 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.14.1463.31942

2 April 2024

1 reference

9 August 2017

volume

23

1 reference

9 August 2017

issue

11

1 reference

9 August 2017

page(s)

1463-1474

1 reference

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

The plasma concentration and LDL-C relationship in patients receiving ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Assessment of hypercholesterolemia control in a managed care organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.14.1463.31942

Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.14.1463.31942

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

2 April 2024

3

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.14.1463.31942

Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment

2 April 2024

7

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.14.1463.31942

2 April 2024

Identifiers

1 reference

9 August 2017

1 reference